LifeArc
@lifearc.bsky.social
Medical research non-profit transforming promising life science ideas into medical breakthroughs that change patients’ lives.
We're proud to partner with Global Alzheimer's Platform Foundation and @ukdri.ac.uk on the Bio-Hermes-002 study, working towards an Alzheimer's test that's scalable, accessible and cost-effective.
t.ly/QWn1R
t.ly/QWn1R
Alzheimer's finger-prick blood test could transform diagnosis, experts say - BBC News
An international trial involving 1,000 volunteers will aim to detect biomarkers associated with the condition.
t.ly
January 19, 2026 at 9:11 AM
We're proud to partner with Global Alzheimer's Platform Foundation and @ukdri.ac.uk on the Bio-Hermes-002 study, working towards an Alzheimer's test that's scalable, accessible and cost-effective.
t.ly/QWn1R
t.ly/QWn1R
Professor Alfredo Iacoangeli and his team at King’s College London are exploring whether patterns of gene expression in blood could be used as an early diagnostic tool for ALS.
We’re funding this project to improve diagnosis of ALS in primary care: https://t.ly/KyRR4
We’re funding this project to improve diagnosis of ALS in primary care: https://t.ly/KyRR4
January 16, 2026 at 10:15 AM
Professor Alfredo Iacoangeli and his team at King’s College London are exploring whether patterns of gene expression in blood could be used as an early diagnostic tool for ALS.
We’re funding this project to improve diagnosis of ALS in primary care: https://t.ly/KyRR4
We’re funding this project to improve diagnosis of ALS in primary care: https://t.ly/KyRR4
We partnered with KisoJi to humanise a novel anti-TROP-2 antibody.
Now in trials with Cancer Research UK, this first-in-class therapy offers new hope for cancer. This was a global effort showcasing the power of our truly collaborative model.
Read more: https://t.ly/_cdM0
Now in trials with Cancer Research UK, this first-in-class therapy offers new hope for cancer. This was a global effort showcasing the power of our truly collaborative model.
Read more: https://t.ly/_cdM0
January 14, 2026 at 9:00 AM
We partnered with KisoJi to humanise a novel anti-TROP-2 antibody.
Now in trials with Cancer Research UK, this first-in-class therapy offers new hope for cancer. This was a global effort showcasing the power of our truly collaborative model.
Read more: https://t.ly/_cdM0
Now in trials with Cancer Research UK, this first-in-class therapy offers new hope for cancer. This was a global effort showcasing the power of our truly collaborative model.
Read more: https://t.ly/_cdM0
Lung conditions place a huge strain on people, health services and the UK economy. With @asthmaandlung.org.uk, we created guidance for a "simple lung test" to be used at GP appointments – cutting delays, improving referral precision and reducing costly hospital visits.
🔗Download: https://t.ly/53l1k
🔗Download: https://t.ly/53l1k
January 13, 2026 at 9:00 AM
Lung conditions place a huge strain on people, health services and the UK economy. With @asthmaandlung.org.uk, we created guidance for a "simple lung test" to be used at GP appointments – cutting delays, improving referral precision and reducing costly hospital visits.
🔗Download: https://t.ly/53l1k
🔗Download: https://t.ly/53l1k
With @innovateuk.bsky.social and Medicines Discovery Catapult, we’re partnering on PACE to accelerate innovation in AMR research.
Read more about how we involve patients: https://www.lifearc.org/work-with-us/patients-community/
Read more about how we involve patients: https://www.lifearc.org/work-with-us/patients-community/
January 10, 2026 at 9:00 AM
With @innovateuk.bsky.social and Medicines Discovery Catapult, we’re partnering on PACE to accelerate innovation in AMR research.
Read more about how we involve patients: https://www.lifearc.org/work-with-us/patients-community/
Read more about how we involve patients: https://www.lifearc.org/work-with-us/patients-community/
Dementia is not a sudden event. But how can we detect it earlier and, in some cases, prevent its onset?
In two weeks, we'll be at The Brain House during the World Economic Forum's Annual Meeting speaking to worldwide experts on how brain health strengthens societies and economies. #WEF26
In two weeks, we'll be at The Brain House during the World Economic Forum's Annual Meeting speaking to worldwide experts on how brain health strengthens societies and economies. #WEF26
January 9, 2026 at 9:02 AM
Dementia is not a sudden event. But how can we detect it earlier and, in some cases, prevent its onset?
In two weeks, we'll be at The Brain House during the World Economic Forum's Annual Meeting speaking to worldwide experts on how brain health strengthens societies and economies. #WEF26
In two weeks, we'll be at The Brain House during the World Economic Forum's Annual Meeting speaking to worldwide experts on how brain health strengthens societies and economies. #WEF26
@ukdri.ac.uk researcher Nathan Skene leads a LifeArc funded project which aims to develop a scalable test that could help inform how these variants influence disease development and progression.
January 8, 2026 at 9:15 AM
@ukdri.ac.uk researcher Nathan Skene leads a LifeArc funded project which aims to develop a scalable test that could help inform how these variants influence disease development and progression.
We are pleased to welcome Matt Owens as our new General Counsel and Company Secretary.
Matt has a wealth of legal and governance expertise, including on fundraising, Phases II and III product development and commercialisation.
Matt has a wealth of legal and governance expertise, including on fundraising, Phases II and III product development and commercialisation.
January 7, 2026 at 9:00 AM
We are pleased to welcome Matt Owens as our new General Counsel and Company Secretary.
Matt has a wealth of legal and governance expertise, including on fundraising, Phases II and III product development and commercialisation.
Matt has a wealth of legal and governance expertise, including on fundraising, Phases II and III product development and commercialisation.
With EMBARC Network, we're supporting the AIR-NET trial. It is investigating if repurposed anti-inflammatory treatments can reduce neutrophilic inflammation and improve respiratory health outcomes in people with bronchiectasis.
@dundee.ac.uk
Learn more: https://www.lifearc.org/project/airnet/
@dundee.ac.uk
Learn more: https://www.lifearc.org/project/airnet/
January 6, 2026 at 9:00 AM
With EMBARC Network, we're supporting the AIR-NET trial. It is investigating if repurposed anti-inflammatory treatments can reduce neutrophilic inflammation and improve respiratory health outcomes in people with bronchiectasis.
@dundee.ac.uk
Learn more: https://www.lifearc.org/project/airnet/
@dundee.ac.uk
Learn more: https://www.lifearc.org/project/airnet/
Every month MND goes undiagnosed is a missed opportunity for treatment and planning.
Our Primer Fund is a dedicated funding stream to support early-stage, high-potential projects that could help speed up diagnosis of MND, particularly ALS, the most common form: https://t.ly/KyRR4
Our Primer Fund is a dedicated funding stream to support early-stage, high-potential projects that could help speed up diagnosis of MND, particularly ALS, the most common form: https://t.ly/KyRR4
January 5, 2026 at 9:00 AM
Every month MND goes undiagnosed is a missed opportunity for treatment and planning.
Our Primer Fund is a dedicated funding stream to support early-stage, high-potential projects that could help speed up diagnosis of MND, particularly ALS, the most common form: https://t.ly/KyRR4
Our Primer Fund is a dedicated funding stream to support early-stage, high-potential projects that could help speed up diagnosis of MND, particularly ALS, the most common form: https://t.ly/KyRR4
Through workshops, surveys and focus groups with patients, clinicians and healthcare professionals, we and @asthmaandlung.org.uk gathered insights from every angle.
These perspectives are now informing a new ‘Target Product Profile’ for diagnostics developers to use: https://t.ly/SGzIH
These perspectives are now informing a new ‘Target Product Profile’ for diagnostics developers to use: https://t.ly/SGzIH
January 2, 2026 at 9:00 AM
Through workshops, surveys and focus groups with patients, clinicians and healthcare professionals, we and @asthmaandlung.org.uk gathered insights from every angle.
These perspectives are now informing a new ‘Target Product Profile’ for diagnostics developers to use: https://t.ly/SGzIH
These perspectives are now informing a new ‘Target Product Profile’ for diagnostics developers to use: https://t.ly/SGzIH
How could technology provide meaningful support to people with MND and their caregivers? Our recent report gives 5 recommendations, based on insights from people living with MND, their caregivers, and the wider community - https://bit.ly/4pgDfYc
December 30, 2025 at 9:00 AM
How could technology provide meaningful support to people with MND and their caregivers? Our recent report gives 5 recommendations, based on insights from people living with MND, their caregivers, and the wider community - https://bit.ly/4pgDfYc
We’re supporting a @manchester.ac.uk trial, exploring the safety and potential of gene therapy to help reduce disease symptoms and prevent brain damage in children with Hunter syndrome.
Read about Ollie, the first child to receive this gene therapy, here: https://t.ly/nOQxK
Read about Ollie, the first child to receive this gene therapy, here: https://t.ly/nOQxK
Hunter syndrome: Boy with rare condition amazes doctors after world-first gene therapy
Oliver has an inherited condition called Hunter syndrome, which causes progressive damage to the body and brain.
t.ly
December 28, 2025 at 9:00 AM
We’re supporting a @manchester.ac.uk trial, exploring the safety and potential of gene therapy to help reduce disease symptoms and prevent brain damage in children with Hunter syndrome.
Read about Ollie, the first child to receive this gene therapy, here: https://t.ly/nOQxK
Read about Ollie, the first child to receive this gene therapy, here: https://t.ly/nOQxK
Looking for a change in the New Year? Consider joining LifeArc and being part of a team that transforms lives.
Visit our careers page: https://www.lifearc.org/careers/
Visit our careers page: https://www.lifearc.org/careers/
December 26, 2025 at 9:15 AM
Looking for a change in the New Year? Consider joining LifeArc and being part of a team that transforms lives.
Visit our careers page: https://www.lifearc.org/careers/
Visit our careers page: https://www.lifearc.org/careers/
We wish U(2OS) a happy holiday season from these osteosarcoma cells showing red G3BP1 stress granules after chemical stress with sodium arsenite, used in an early validation assay for one of our MND projects.
Photo: Rebecca Girling
Photo: Rebecca Girling
December 23, 2025 at 9:15 AM
We wish U(2OS) a happy holiday season from these osteosarcoma cells showing red G3BP1 stress granules after chemical stress with sodium arsenite, used in an early validation assay for one of our MND projects.
Photo: Rebecca Girling
Photo: Rebecca Girling
Involving patients in programmes like this can speed up and prioritise projects that will create effective, tolerable treatments for everyone affected by MND.
December 22, 2025 at 9:00 AM
Involving patients in programmes like this can speed up and prioritise projects that will create effective, tolerable treatments for everyone affected by MND.
We’re funding a new clinical trial at @kingscollegelondon.bsky.social to test nasal insulin spray for Phelan-McDermid syndrome, which affects movement, speech, learning, sleep, digestion and mood. Co-designed with families, the trial aims to recruit 100 children and young adults.
December 19, 2025 at 4:12 PM
We’re funding a new clinical trial at @kingscollegelondon.bsky.social to test nasal insulin spray for Phelan-McDermid syndrome, which affects movement, speech, learning, sleep, digestion and mood. Co-designed with families, the trial aims to recruit 100 children and young adults.
2025 has been quite the year! It's nearly impossible to wrap up succinctly, with so many incredible projects underway! Our sincerest thanks to all of our partners and colleagues for making this year such an impactful one.
December 18, 2025 at 9:00 AM
2025 has been quite the year! It's nearly impossible to wrap up succinctly, with so many incredible projects underway! Our sincerest thanks to all of our partners and colleagues for making this year such an impactful one.
We have recently signed two new antibody development collaboration agreements with Laigo Bio, an innovative biotech company.
December 17, 2025 at 9:00 AM
We have recently signed two new antibody development collaboration agreements with Laigo Bio, an innovative biotech company.
New drugs could selectively target Huntington’s disease-causing forms of the huntingtin gene – potentially preventing the expansion of protein that is toxic to cells.
We’re funding this drug development project led by Prof Sarah Tabrizi as part of the @ukdri.ac.uk Translation Awards.
We’re funding this drug development project led by Prof Sarah Tabrizi as part of the @ukdri.ac.uk Translation Awards.
December 16, 2025 at 9:15 AM
New drugs could selectively target Huntington’s disease-causing forms of the huntingtin gene – potentially preventing the expansion of protein that is toxic to cells.
We’re funding this drug development project led by Prof Sarah Tabrizi as part of the @ukdri.ac.uk Translation Awards.
We’re funding this drug development project led by Prof Sarah Tabrizi as part of the @ukdri.ac.uk Translation Awards.
We're co-funding the TIARA trial with Aplastic Anaemia Trust. The trial, conducted at @kingscollegenhs.bsky.social, is investigating the safety and optimal dosage of expanded autologous T regulatory cells to treat patients with aplastic anaemia.
https://t.ly/r2ECR
https://t.ly/r2ECR
December 11, 2025 at 9:15 AM
We're co-funding the TIARA trial with Aplastic Anaemia Trust. The trial, conducted at @kingscollegenhs.bsky.social, is investigating the safety and optimal dosage of expanded autologous T regulatory cells to treat patients with aplastic anaemia.
https://t.ly/r2ECR
https://t.ly/r2ECR
1 in 5 people will develop a chronic lung disease, yet asthma, COPD, ILD and bronchiectasis are often misdiagnosed. With @asthmaandlung.org.uk, we've shared guidance for developers to create a primary care test that helps people get the right treatment sooner.
🔗 Read the guide: https://t.ly/GkoS7
🔗 Read the guide: https://t.ly/GkoS7
December 10, 2025 at 9:15 AM
1 in 5 people will develop a chronic lung disease, yet asthma, COPD, ILD and bronchiectasis are often misdiagnosed. With @asthmaandlung.org.uk, we've shared guidance for developers to create a primary care test that helps people get the right treatment sooner.
🔗 Read the guide: https://t.ly/GkoS7
🔗 Read the guide: https://t.ly/GkoS7
We partnered with KisoJi Biotechnology to humanise novel antibodies targeting the cancer target TROP-2.
Using our humanisation expertise, we developed stable, potent antibodies that demonstrated tumour reduction in preclinical models. 🧬💥 t.ly/xEBFj
Using our humanisation expertise, we developed stable, potent antibodies that demonstrated tumour reduction in preclinical models. 🧬💥 t.ly/xEBFj
December 8, 2025 at 10:29 AM
We partnered with KisoJi Biotechnology to humanise novel antibodies targeting the cancer target TROP-2.
Using our humanisation expertise, we developed stable, potent antibodies that demonstrated tumour reduction in preclinical models. 🧬💥 t.ly/xEBFj
Using our humanisation expertise, we developed stable, potent antibodies that demonstrated tumour reduction in preclinical models. 🧬💥 t.ly/xEBFj
Proposals from 31 countries across 5 continents, narrowed to 4 groundbreaking research projects that we're supporting to explore whether existing medicines can be repurposed to treat motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS). Meet the projects ⬇️
December 5, 2025 at 12:00 PM
Proposals from 31 countries across 5 continents, narrowed to 4 groundbreaking research projects that we're supporting to explore whether existing medicines can be repurposed to treat motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS). Meet the projects ⬇️
Living with motor neuron disease (MND) brings significant daily challenges. Our new report shares insights from people living with MND, their caregivers, and the wider community about the most pressing issues, and how technology could help: https://bit.ly/4pgDfYc
December 4, 2025 at 9:00 AM
Living with motor neuron disease (MND) brings significant daily challenges. Our new report shares insights from people living with MND, their caregivers, and the wider community about the most pressing issues, and how technology could help: https://bit.ly/4pgDfYc